Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:1196-1203
doi: 10.1161/CIRCULATIONAHA.106.670075
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Callans, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Callans, D. J.
Related Collections
Right arrow Electrophysiology
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2007;116:1196-1203.)
© 2007 American Heart Association, Inc.


Controversies in Cardiovascular Medicine

Do patients with hemodynamically tolerated ventricular tachycardia require implantable cardioverter-defibrillators?

Response to Callans


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Jesús Almendral, MD, PhD; Mark E. Josephson, MD

Although conventional wisdom might be against the use of implantable cardioverter-defibrillators (ICDs) for well-tolerated ventricular tachycardia (VT), the reverse (ie, implantation of ICDs) is intuitively more likely. The logic would be as follows: If we are implanting ICDs for primary prevention because patients are at risk of malignant ventricular arrhythmias, how could we not implant in patients who have already had a sustained VT (ie, the paradigm of a malignant arrhythmia)? Such a dilemma needs the discourse of scientific information that demonstrates that tolerated VT, adequately treated, is truly a malignant arrhythmia. Despite Dr Callans’ convincing discussion of secondary-prevention ICD trials, these trials do not help scientifically simply because patients with tolerated VT were explicitly excluded from them. The most important information derives from observational studies on catheter ablation, including almost 800 patients altogether. It is claimed that ablation does not "appear sufficiently protective" on the basis of a high rate of recurrent VT and total mortality. However, recurrent tolerated VT is overestimated by the ICD and is not a catastrophic event; it allows further therapy. Total mortality is high, but sudden death is low (2.5% after procedures considered successful). One of the series quoted as having high mortality (that of Calkins et al) is the series with the highest ICD implantation rate (79% had ICDs), suggesting that most deaths were nonarrhythmic and/or that the ICD contributed to the outcome. Thus, catheter ablation series are consistent with observational series from the 1980s . . . [Full Text of this Article]